Skip to main content
[Preprint]. 2024 Aug 22:2024.08.21.608990. [Version 1] doi: 10.1101/2024.08.21.608990

Fig. 3. NuP-4A effect on biomarkers to track PVLD.

Fig. 3.

A-G, Lung levels of mRNA biomarkers for indicated disease endpoints for NuP-4A treatment for 5-21 d with final samples at 49 d after SeV infection as shown in Fig. 2B. Data are representative of three separate experiments with n=8 animals per condition in each experiment (mean ± s.e.m.). *P <0.05 using ANOVA and Tukey correction.